Eric M. Green - 07 May 2024 Form 4 Insider Report for WEST PHARMACEUTICAL SERVICES INC (WST)

Source evidence Original filing metadata and source links for verification. 5 source fields
SEC form
4
Accepted by SEC
09 May 2024, 15:38:13 UTC
Prior SEC filing
08 May 2024
Next SEC filing
02 Jul 2024
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Luis Cantarero

Key filing fact

Eric M. Green filed Form 4 for WEST PHARMACEUTICAL SERVICES INC (WST) on 09 May 2024.

Key facts

  • This page summarizes Eric M. Green's Form 4 filing for WEST PHARMACEUTICAL SERVICES INC (WST).
  • 11 reported transactions and 4 derivative rows are listed below.
  • Accepted by SEC: 09 May 2024, 15:38.

Change

  • Previous filing in this sequence was filed on 08 May 2024.
  • Current net transaction value: -$19,782,550.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

WST transaction

Common Stock

Options Exercise

Transaction value
$534,552
Shares
+9,316
Change %
+6.1%
Price
$57.38
Shares after
162,224
Date
07 May 2024
Ownership
Direct
Footnotes
F1
WST transaction

Common Stock

Options Exercise

Transaction value
$899,948
Shares
+15,684
Change %
+9.7%
Price
$57.38
Shares after
177,908
Date
07 May 2024
Ownership
Direct
Footnotes
F1
WST transaction

Common Stock

Options Exercise

Transaction value
$2,445,240
Shares
+41,000
Change %
+23%
Price
$59.64
Shares after
218,908
Date
07 May 2024
Ownership
Direct
Footnotes
F1
WST transaction

Common Stock

Sale

Transaction value
$3,415,636
Shares
-9,316
Change %
-4.2%
Price
$366.64
Shares after
209,952
Date
07 May 2024
Ownership
Direct
Footnotes
F1, F2
WST transaction

Common Stock

Sale

Transaction value
$5,750,678
Shares
-15,684
Change %
-7.5%
Price
$366.66
Shares after
193,908
Date
07 May 2024
Ownership
Direct
Footnotes
F1, F2
WST transaction

Common Stock

Sale

Transaction value
$15,032,736
Shares
-41,000
Change %
-21%
Price
$366.65
Shares after
152,908
Date
07 May 2024
Ownership
Direct
Footnotes
F1, F2
WST transaction

Common Stock

Options Exercise

Transaction value
$536,760
Shares
+9,000
Change %
+5.9%
Price
$59.64
Shares after
161,908
Date
07 May 2024
Ownership
Direct
Footnotes
F1

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

WST transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-9,316
Change %
-100%
Price
$0.000000*
Shares after
0
Date
07 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
9,316
Exercise price
$57.38
WST transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-15,684
Change %
-100%
Price
$0.000000*
Shares after
0
Date
07 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
15,684
Exercise price
$57.38
WST transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-41,000
Change %
-47%
Price
$0.000000
Shares after
45,732
Date
07 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
41,000
Exercise price
$59.64
WST transaction Derivative

Stock Option (Right to Buy)

Options Exercise

Transaction value
$0
Shares
-9,000
Change %
-20%
Price
$0.000000
Shares after
36,732
Date
07 May 2024
Ownership
Direct
Underlying class
Common Stock
Underlying amount
9,000
Exercise price
$59.64
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

The shares reported were acquired by the Reporting Person from exercising a portion of a stock option award expiring in either 2025 or 2026, pursuant to Rule 10b5-1 Trading Plan. The purchase and sale reported on this Form 4 was completed pursuant to a Rule 10b5-1 Trading Plan adopted by the Reporting Person on 11/17/2023.

Footnote F2

The price reported in Column 4 is a weighted average price.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .